ABSTRACT
Ligands are compounds that generally bind specifically to a receptor. The chemistry of Ligand–Receptor interactions implies some restrictions: in the control mechanisms of binding of a ligand to its specific receptor. G-protein-coupled receptors play essential roles in intracellular signaling, therefore their implication in a wide range of diseases, comprising the main pathophysiological mechanisms: inflammation, from infective conditions to proliferative diseases (cancer). Mogamulizumab is a monoclonal antibody that targets the chemokine receptor type 4, and it was recently approved for the treatment of adult T cell leukemia. The active transport of nano-aggregates is achieved using vectors or ligands that bind specifically to receptors that are overexpressed in tumor cells. Oncology is one of the most approached fields by researchers in terms of specific targeted therapy. So, it has been demonstrated that receptors (localized at the cell surface) are specific or are overexpressed by cancer cells.
